ArticlePharmaceutics2022
A Study on the Anti-NF-κB, Anti-
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Comparative Genome-Wide Association Studies of Metabolites and Grain-Related Traits in Common Wheat.Plant biotechnology journal · 2026Article
- Dietary supplementation with Cuscuta chinensis improves ovarian function and production performance in aged laying hens via modulation of steroid hormone biosynthesis and gut microbiota.Poultry science · 2026Article
- Anaerobic self-induced fermentation: a green bioprocessing strategy for enhancing extraction efficiency and bioactivities of flavonoids from Erigeron breviscapus (Vant.) Hand-Mazz.Archives of microbiology · 2026Article
- Explore the changes of metabolites in feces and serum of acute pancreatitis patients with different etiologies by LC-MS based metabolomics strategy.Frontiers in pharmacology · 2025Article
- Exploring molecular mechanisms of postoperative delirium through multi-omics strategies in plasma exosomes.Scientific reports · 2024Article
- Progress and promise of alternative animal and non-animal methods in biomedical research.Archives of toxicology · 2023Review
- Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells.Biomedicines · 2023Article
- Antibacterial efficacy of sodium dichloroisocyanurate and 2-hydroxyisocaproic acid intracanal medicaments on Enterococcus faecalis: A comparative in-vitro study.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
introductionGibberellins (GA) are terpenoids that serve as important plant hormones by acting as growth and response modulators against injuries and parasitism. In this study, we investigated the in vitro anti-NF-κB, anti-
methodsGA4 and GA7 in vitro toxicity was determined by MTT method, and nontoxic concentrations were then tested to evaluate the GA4 and GA7 anti-NF-κB activity in LPS-activated RAW-luc macrophage cell culture (luminescence assay). GA4 in silico anti-NF-κB activity was evaluated by molecular docking with the software "AutoDock Vina", "MGLTools", "Pymol", and "LigPlot+", based on data obtained from "The Uniprot database", "Protein Data Bank", and "PubChem database". The GA4 and GA7 in vitro anti-
resultsOur data show that GA4 at 30 µM is nontoxic and capable of reducing 32% of the NF-κB activation on RAW-luc macrophages in vitro. In vitro results were confirmed via molecular docking assay (in silico), since GA4 presented binding affinity to NF-κB p65 and p50 subunits. GA7 did not present anti-NF-κB effects, but exhibited anti-
conclusionOur study provides preclinical evidence indicating that GA4 and GA7 have a favorable low toxicity profile. The study also points to GA4 and GA7 interference with the NF-κB via, anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.